• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    How Biogen’s (BIIB) At-Home LEQEMBI Injections Could Reframe the Alzheimer’s Treatment Investment Story

    Simply Wall St·09/03/2026 00:46:35
    Listen to the news
    • In August 2026, Eisai and Biogen announced that once-weekly LEQEMBI IQLIK subcutaneous injections are now available in the U.S. for at-home initiation and maintenance treatment of early Alzheimer’s disease, offering an alternative to intravenous infusions and supported by extensive patient, caregiver, and provider resources.
    • This first-of-its-kind at-home anti-amyloid regimen could meaningfully lower treatment barriers for eligible Alzheimer’s patients by improving convenience, flexibility, and healthcare system efficiency.
    • Next, we’ll examine how Biogen’s launch of at-home LEQEMBI IQLIK dosing could reshape its investment narrative around Alzheimer’s care.

    We've uncovered the 11 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

    Biogen Investment Narrative Recap

    To own Biogen, you need to believe its newer neurology launches can offset pressure on older MS drugs and margin headwinds. LEQEMBI IQLIK’s at-home, once-weekly injections reinforce that Alzheimer’s is the key near term catalyst, but the biggest risk remains execution: can Biogen translate clinical success into broad, reimbursed use fast enough in the face of payer scrutiny and competition? This launch looks directionally positive for that thesis rather than a fundamental shift.

    Among recent developments, Biogen’s completed acquisition of RayThera, adding early stage immunology assets, is most relevant in context. While LEQEMBI IQLIK addresses the near term Alzheimer’s opportunity, RayThera highlights how dependent Biogen still is on a handful of growth drivers and why building a broader pipeline matters for future catalysts if LEQEMBI or other launches underperform.

    Yet beneath the promise of at home Alzheimer’s treatment, investors should also be aware of the unresolved risk that...

    Read the full narrative on Biogen (it's free!)

    Biogen's narrative projects $10.6 billion revenue and $2.3 billion earnings by 2029. This requires 2.3% yearly revenue growth and about a $0.9 billion earnings increase from $1.4 billion today.

    Uncover how Biogen's forecasts yield a $227.59 fair value, in line with its current price.

    Exploring Other Perspectives

    BIIB 1-Year Stock Price Chart
    BIIB 1-Year Stock Price Chart

    Some of the lowest estimate analysts were assuming roughly flat revenue around US$10.2 billion and only US$1.8 billion of earnings by 2029, so compared with the LEQEMBI centered upside story, their view is far more cautious that access hurdles and pricing pressure could blunt the impact of at home dosing, which is exactly why it can be useful for you to weigh several contrasting viewpoints before deciding how this new launch might shift the long term picture.

    Explore 5 other fair value estimates on Biogen - why the stock might be worth 19% less than the current price!

    Decide For Yourself

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    No Opportunity In Biogen?

    Our daily scans reveal stocks with breakout potential. Don't miss this chance:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.